Changes necessitated by COVID will drive unprecedented transformation of industry.
Jose-Carlos Gutiérrez-Ramos, PhD
Advertisement
Chief Science Officer, Danaher
Articles by Jose-Carlos Gutiérrez-Ramos, PhD
Advertisement
Latest Updated Articles
Why the Pandemic is Rewriting the Biopharma Rule BookPublished: August 10th 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
How are Other Players in the Healthcare Industry Reacting to Drug Pricing Negotiations?
4
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
5
